Dexpramipexole

Dexpramipexole is the mirror-image enantiomer of pramipexole, the S-form of which is a potent dopamine agonist used in Parkinson disease and restless legs syndrome. The R-configuration retains only weak dopamine-receptor affinity, which allowed developers to give much higher doses in pursuit of a separate, mitochondrial mechanism: the compound binds F1Fo ATP synthase and enhances mitochondrial ATP production, and it accumulates in the brain ^[3]. This repositioning made dexpramipexole a candidate neuroprotectant for diseases with a bioenergetic component.

Early clinical results were encouraging. In a two-part, double-blind phase 2 study in amyotrophic lateral sclerosis, dexpramipexole was safe and well tolerated, and the higher-dose arm showed a dose-dependent attenuation of functional decline and a statistically significant advantage on a joint rank test combining function and mortality, a signal strong enough to justify a definitive trial ^[1]. The hopes it raised, however, were not confirmed: the large randomized phase 3 EMPOWER trial in 943 patients found no difference from placebo on the combined assessment of function and survival or on any prespecified endpoint, and it was associated with a higher incidence of neutropenia ^[2].

Mechanistic interest in the compound persisted after the ALS program ended. In experimental stroke, dexpramipexole increased mitochondrial ATP production in neurons and glia, reduced energy failure and calcium overload during oxygen-glucose deprivation, and, given after the insult at doses consistent with those used in ALS patients, reduced infarct size and improved neurological scores, with drug concentrations in the ischemic penumbra matching those found protective in vitro ^[3]. Its excellent brain penetration and human safety record led the authors to argue for realistic translational potential in stroke, underscoring that a clinical failure in one indication does not erase a compound's bioenergetic pharmacology.

Mixed clinical evidence; positive phase 2 not confirmed by a negative phase 3, ongoing preclinical bioenergetic data

Across phase 2 and phase 3 programs dexpramipexole was generally well tolerated, but the large EMPOWER trial identified neutropenia as a notable adverse effect, occurring in about 8 percent of treated patients versus 2 percent on placebo, which warrants blood-count monitoring in any use ^[2]. Other adverse events were broadly similar to placebo. As an investigational compound without an approved indication in this mechanism, it should be used only under clinical supervision; it is not a supplement, and its enantiomeric parent's dopaminergic cautions are a reminder to respect stereochemical specificity.

Dexpramipexole was developed by Knopp Biosciences and licensed to Biogen Idec, which advanced it as a mitochondrial neuroprotectant for amyotrophic lateral sclerosis. After a promising 2011 phase 2 study, the phase 3 EMPOWER trial reported in 2013 showed no benefit, ending its ALS development. The molecule was later repurposed by Areteia Therapeutics toward eosinophilic conditions such as asthma, exploiting a separate effect on eosinophils, while its mitochondrial and neuroprotective properties continued to attract preclinical study.

Dexpramipexole is frequently cited as a cautionary tale in ALS drug development, a compound with a clean mechanism and a hopeful phase 2 that did not survive a rigorous phase 3. At the same time it retains scientific credibility as a genuine ATP-synthase-targeting bioenergetic agent with strong brain penetration, and it is discussed in stroke and mitochondrial pharmacology literature. It has no standing as a consumer nootropic and should be understood as an investigational drug.